Drug & intervention

alectinib

RxCUI 1727455

Clinical trials39
Recruiting5
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

39 shown
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLCNCT06765109 · 2025-07-17
RECRUITING
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant TherapyNCT06862869 · 2025-04-30
RECRUITING
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangementsNCT05987644 · 2024-03-07
RECRUITING
Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib BloodlevelsNCT05525338 · 2022-03-23
RECRUITING
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)NCT04302025 · 2020-11-06
RECRUITING
A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)NCT06624059 · 2024-11-18
COMPLETED
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLCNCT06709274 · 2024-11-01
NOT_YET_RECRUITING
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung CancerNCT06532149 · 2024-08-05
UNKNOWN
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.NCT05834348 · 2023-06-23
COMPLETED
SMMART Adaptive Clinical Treatment (ACT) TrialNCT05238831 · 2023-01-30
WITHDRAWN
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)NCT05170204 · 2022-11-01
ACTIVE_NOT_RECRUITING
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsNCT04644315 · 2021-05-24
TERMINATED
Alectinib in Neo-adjuvant Treatment of Stage III NSCLCNCT05015010 · 2021-05-20
ACTIVE_NOT_RECRUITING
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.NCT04647110 · 2020-12-14
COMPLETED
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyNCT04591431 · 2020-10-07
UNKNOWN
Alectinib in Combination With Bevacizumab in ALK Positive NSCLCNCT03779191 · 2020-04-08
COMPLETED
Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment PatternsNCT04351334 · 2020-03-01
COMPLETED
Brazilian Lung Immunotherapy StudyNCT05081674 · 2020-01-01
COMPLETED
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerNCT03737994 · 2019-07-25
TERMINATED
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)NCT03944772 · 2019-06-25
ACTIVE_NOT_RECRUITING
Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer PatientsNCT04708639 · 2019-06-19
UNKNOWN
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung CancerNCT03596866 · 2019-04-19
COMPLETED
ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung CancerNCT03445000 · 2018-11-06
TERMINATED
A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) InhibitorsNCT03546894 · 2018-07-23
COMPLETED
Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in KoreaNCT03271554 · 2017-11-09
COMPLETED
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)NCT03178552 · 2017-09-22
ACTIVE_NOT_RECRUITING
A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLCNCT03202940 · 2017-09-14
ACTIVE_NOT_RECRUITING
A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung CancerNCT03155009 · 2017-07-10
COMPLETED
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive CancerNCT03194893 · 2017-07-05
COMPLETED
A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid CancerNCT03131206 · 2017-06-19
TERMINATED
Deciphering Antitumour Response and Resistance With INtratumour HeterogeneityNCT02314481 · 2017-05-12
COMPLETED
A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)NCT02838420 · 2016-08-03
COMPLETED
Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and CrizotinibNCT02604342 · 2015-11-03
COMPLETED
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung CancerNCT02521051 · 2015-09-28
TERMINATED
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer ParticipantsNCT02075840 · 2014-08-19
COMPLETED
A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)NCT02013219 · 2014-04-03
COMPLETED
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)NCT01871805 · 2013-09-30
COMPLETED
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib TreatmentNCT01801111 · 2013-06-20
COMPLETED
Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor TherapyNCT02271139
NO_LONGER_AVAILABLE

Conditions being studied

Non-small Cell Lung Cancer17Carcinoma, Non-Small-Cell Lung3Lung Cancer3Anaplastic Lymphoma Kinase-positive2Neoplasms2Non Small Cell Lung Cancer2Non-Small-Cell Lung Carcinoma2Advanced Breast Carcinoma1Advanced Malignant Solid Neoplasm1Advanced Ovarian Carcinoma1Advanced Pancreatic Carcinoma1Advanced Prostate Carcinoma1Advanced Sarcoma1ALK Gene Mutation1ALK Gene Rearrangement Positive1ALK-positive Non-small Cell Lung Cancer (NSCLC)1ALK-positive NSCLC1ALK+ Advanced NSCLC1Anaplastic Lymphoma Kinase Gene Mutation1Anaplastic Lymphoma Kinase Gene Translocation1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.